Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
Under what circumstances would you treat prostate cancer without a biopsy?
How do you manage bladder spasms during pelvic radiotherapy?
How do you manage malignancies in patients with Birt-Hogg-Dubé syndrome (BHD)? Is there concern for increased radiosensitivity?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
